Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: CURTM	5/31/2009 8:37:33 AM
	Read Replies (3) of 78636

Has anyone looked at PPDI? Pharmaceutical Prod Dev. (PPDI). They have been beaten down to around $20/share based on a slight EPS miss last qtr. No Debt. Large Cash Balance and Just increased their Dividend rate. Yield close to 3% Drug companies use these Contract Resource Organizations (CROs) to assist in getting drugs to market. PE is currently around 12 whereas historically it is running around 21. Many say that the large drug companies will continue to outsource this function and that the trend will continue. I think it is a strong buy around $20 per share for a long term investor. This may be considered more of a growth stock than Value stock based on the PE ratios involved but I thought I would mention it Any input?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next